Results
PONV, RA
ADVERSE EVENTS, SECONDARY
The study population comprised 204 randomly coded patients in Group RR (n = 102) and Group RA (n = 102) (Fig. 
CONSORT diagram of patient recruitmentThe demographic and surgical characteristics of the patients are listed in Table 
Demographic characteristics for each groupNote: PONV occurred on 2 (2.0%) occasions in group RR and 12 (11.8%) occasions in group RA (p = 0.006), and spontaneously resolved without drug treatment in all cases in the two groups (Table 
Primary and secondary outcomes for each groupNote: The time to awakening in Group RR (200.6 ± 94.6 s) was significantly shorter than that in Group RA (283.5 ± 183.1 s) (p < 0.001). However, there was no significant difference in the length of stay in the PACU or the total remimazolam dose between Groups RR and RA. There was no significant difference in the incidence of adverse events, such as low SpOCompared with those at T0, the MAP, HR, RR and SpO
Changes in MAP, HR, RR, SpOChanges in MAP (